PRNewsWire
07 Jun 2026, 20:45 UTC · 17h ago
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
PRNewsWire
07 Jun 2026, 20:45 UTC · 17h ago
Story key points
3 claims · impact-rated
Phase 3 VESALIUS-CV subgroup data shows Repatha reduced the risk of major cardiovascular events (3-P MACE) by 29% in high-risk diabetes patients. — Strong clinical efficacy in a high-risk subgroup supports expanded utilization and market share for Repatha in the cardiometabolic space.
+0.60Repatha's cardiovascular benefits were observed regardless of whether patients were also using SGLT2 inhibitors or GLP-1 receptor agonists. — This positions Repatha as a complementary therapy rather than a competitor to the dominant GLP-1 weight-loss and diabetes drugs.
+0.40Amgen's real-world evidence indicates low patient persistence and adherence to GLP-1 therapies within the first year of treatment. — While highlighting a gap for new strategies, it suggests that real-world outcomes for the GLP-1 class may be lower than clinical trial expectations.
-0.20Ticker attribution
Continue reading
6 related stories
Top 2 movers · tap to explore
Model heads
The company announced positive Phase 3 subgroup results showing Repatha significantly reduces cardiovascular event risks in high-risk diabetes patients.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
